Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.75 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8286344 | 0.93 | PDE11A (0.64) | PDE11APIK3CBPIK3CDPIK3CAKDM4E | |
| SCHEMBL8286346 | 0.91 | PDE11A (0.61) | PDE11APIK3CBPIK3CDPIK3CAKDM4E | |
| SCHEMBL8286342 | 0.90 | PDE11A (0.60) | PDE11APIK3CBPIK3CDPIK3CAKDM4E | |
| SCHEMBL8285166 | 0.90 | PDE11A (0.60) | PDE11APIK3CBPIK3CDPIK3CAKDM4E | |
| SCHEMBL5871598 | 0.88 | PDE11A (0.58) | PDE11APIK3CBPIK3CDPIK3CAKDM4E | |
| SCHEMBL5871831 | 0.86 | PDE11A (0.57) | PDE11APIK3CBPIK3CDPIK3CAALDH1A1 | |
| SCHEMBL8285154 | 0.85 | PDE11A (1.00) | PDE11APIK3CBPIK3CDPIK3CAKDM4E | |
| SCHEMBL8287870 | 0.85 | PDE11A (0.56) | PDE11APIK3CBPIK3CDPIK3CAKDM4E | |
| SCHEMBL8285164 | 0.85 | PDE11A (0.55) | PDE11APIK3CBPIK3CDPIK3CAKDM4E | |
| SCHEMBL8285153 | 0.84 | PDE11A (0.54) | PDE11APIK3CBPIK3CDPIK3CAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109196-B2 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-24 | — | — | US | disclosed |
| US-6964971-B2 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-11-15 | — | — | US | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005091857-A2 | 1,6-NAPHTHYRIDINE AND 1,8-NAPHTHYRIDINE DERIVATIVES AND THEIR USE TO TREAT DIABETES AND RELATED DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-06 | — | — | WO | disclosed |
| US-6900205-B2 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-08-12 | — | — | US | disclosed |
| EP-1432710-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-6677352-B1 | 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders | BAYER PHARMACEUTICALS CORPORATION | 2004-01-13 | — | — | US | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003027112-A1 | 1, 8-NAPHTHYRIDINE DERIVATIVES AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157875-A1 | 1, 6-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, NQO1, UQCRC1 | PDE11A 3297/4885PIK3CB 3895/4885PIK3CD 3220/4885 |
| US-20040209866-A1 | 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders | SLC5A1, NQO1, GLP1R | PDE11A 3053/4885PIK3CB 3808/4885PIK3CD 3330/4885 |
| US-20040014751-A1 | 1,8-Naphthyridine derivatives and their use to treat diabetes and related disorders | UQCRC1, GLP1R, SLC5A1 | PDE11A 3400/4885PIK3CB 3982/4885PIK3CD 3604/4885 |
| US-20060189609-A1 | 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders | GLP1R, UQCRC1, SLC5A1 | PDE11A 2977/4885PIK3CB 3974/4885PIK3CD 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.